Ventyx’s Oral NLRP3 Inhibitor May Complicate Big Pharma IL-6 Antibody Plans

 
• By Joseph Haas
  
Cardiology
Ventyx says its NLRP3 inhibitor can reduce cardiovascular risk in obese patients (Shutterstock)

More from Strategy

More from Business